(secondQuint)Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612.

 This study will assess the long-term protection offered by the new meningococcal vaccine 134612 compared to Meningitec cent up to 4 years after vaccination of toddlers.

 Subjects were previously vaccinated at 12 to 23 months of age with GSK Biologicals' meningococcal vaccine 134612 or Meningitec cent .

 All subjects received at least one dose of Priorix-Tetra cent .

 This extension phase starts 24 months after vaccination and the subjects who were vaccinated in the primary study will be enrolled in this extension study.

 No new subjects will be enrolled.

 The subjects will have a blood sample taken at 24, 36 and 48 months after primary vaccination.

 At Year 4 subjects will be boosted with the same meningococcal vaccine as given in the primary study, i.

e.

 either the new meningococcal vaccine GSK 134612 or Meningitec cent .

 Blood samples will be taken 1 and 12 months after the booster vaccination.

.

 Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612@highlight

Subjects were previously vaccinated at 12 to 23 months of age.

 This extension study starts 24 months after vaccination and the subjects who were vaccinated in the primary study will be enrolled in this extension phase.

 No new subjects will be enrolled.

